Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | AKT1 | P31749 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL567235 | 0.81 | KMT2A (0.54) | MEN1KMT2AHTTL3MBTL1NPC1 | |
| SCHEMBL20163753 | 0.79 | MEN1 (0.53) | MEN1KMT2AHTTL3MBTL1NPC1 | |
| SCHEMBL8773482 | 0.78 | MEN1 (0.69) | MEN1KMT2AHTTL3MBTL1NPC1 | |
| SCHEMBL17258048 | 0.78 | KMT2A (0.51) | MEN1KMT2AHTTL3MBTL1NPC1 | |
| SCHEMBL17258003 | 0.77 | MEN1 (0.54) | MEN1KMT2AHTTL3MBTL1NPC1 | |
| SCHEMBL17467189 | 0.75 | KMT2A (0.49) | MEN1KMT2AHTTL3MBTL1NPC1 | |
| SCHEMBL16400574 | 0.75 | MEN1 (0.49) | MEN1KMT2AHTTL3MBTL1NPC1 | |
| SCHEMBL27517789 | 0.75 | MEN1 (0.49) | MEN1KMT2AHTTL3MBTL1NPC1 | |
| SCHEMBL16399504 | 0.75 | MEN1 (0.46) | MEN1KMT2AHTTL3MBTL1NPC1 | |
| SCHEMBL564589 | 0.74 | BLM (0.49) | MEN1KMT2AHTTL3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2120965-B1 | N-HALOGENATED AMINO COMPOUNDS AND DERIVATIVES | NOVABAY PHARMACEUTICALS INC (US) | 2014-11-05 | — | — | EP | disclosed |
| US-8415497-B2 | N-halogenated amino compounds and derivatives | NOVABAY PHARMACEUTICALS, INC. (US) | 2013-04-09 | — | — | US | disclosed |
| US-20100311791-A1 | N-HALOGENATED AMINO COMPOUNDS AND DERIVATIVES | NOVABAY PHARMACEUTICALS, INC. | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311791-A1 | N-HALOGENATED AMINO COMPOUNDS AND DERIVATIVES | DCTD, DDC, DAO | MEN1 2339/4885KMT2A 1714/4885HTT 2028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.